Program
epcoritamab
Also written as “Epcoritamab”, “Epcoritamab (monotherapy)” and “Epcoritamab (maintenance)”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Lymphoma, B-Cell · Lymphoma, Non-Hodgkin, led by Genmab.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genmab | 1312 open or running | phase 3since Nov 9, 2020 | Jun 7, 2018 | Mar 2027phase 2 · NCT05451810 |
Also a collaborator on its studies: AbbVie and Eli Lilly.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 7, 2018First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03625037 · 666 enrolled · United States, Australia, Canada and more
- Aug 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04542824 · 78 enrolled · Japan
- Oct 27, 20202 phase 2 studiesNCT04663347, NCT04623541
- Nov 9, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04628494 · 483 enrolled · United States, Australia, Austria and more
- Jan 18, 2022Phase 2 study in Lymphoma, B-CellNCT05201248 · 49 enrolled · China
- Jan 21, 2022Phase 1 study in Lymphoma, Non-HodgkinNCT05206357 · 17 enrolled · United States, Australia, Belgium and more
- Jun 3, 2022Phase 3 study in Lymphoma, FollicularNCT05409066 · 549 enrolled · United States, Argentina, Australia and more
- Jul 6, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05451810 · 184 enrolled · United States, Puerto Rico
- Nov 29, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05660967 · 111 enrolled · United States, Austria, Belgium and more
- Dec 20, 2023Phase 3 study in Lymphoma, FollicularNCT06191744 · 1,095 enrolled · United States, Australia, Belgium and more
- Jul 11, 2024Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06508658 · 379 enrolled · United States, Argentina, Australia and more
- Nov 6, 2025Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07226752 · 72 enrolled · China
- Nov 4, 2026Primary completion moved from 2026-09 to 2027-10Date moved laterphase 2 · +13 months · NCT05201248
Ahead
- Mar 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05451810
- Sep 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04542824
- Sep 30, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04663347
- Oct 2027Primary completion: phase 2 study in Lymphoma, B-CellNCT05201248
TargetBeta
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07226752Lymphoma, Large B-Cell, Diffuse · China | 3 | Active, not recruiting | Oct 13, 2025 | 72 |
| NCT06508658Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 2028 | 379 |
| NCT06191744Lymphoma, Follicular · United States, Australia, Belgium and more | 3 | Active, not recruiting | Nov 2037 | 1,095 |
| NCT05660967Lymphoma, Large B-Cell, Diffuse · United States, Austria, Belgium and more | 2 | Terminated | Jun 10, 2026 | 111 |
| NCT05451810Lymphoma, Large B-Cell, Diffuse · United States, Puerto Rico | 2 | Active, not recruiting | Mar 2027 | 184 |
| NCT05409066Lymphoma, Follicular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 2029 | 549 |
| NCT05206357Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 1 | Active, not recruiting | Nov 2028 | 17 |
| NCT05201248Lymphoma, B-Cell · China | 2 | Active, not recruiting | Oct 2027 | 49 |
| NCT04628494Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Active, not recruiting | Oct 13, 2025 | 483 |
| NCT04663347Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more | 2 | Active, not recruiting | Sep 30, 2027 | 543 |
| NCT04623541Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 2 | Active, not recruiting | Dec 2027 | 194 |
| NCT04542824Lymphoma, Large B-Cell, Diffuse · Japan | 2 | Active, not recruiting | Sep 2027 | 78 |
| NCT03625037Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more | 2 | Active, not recruiting | Jan 2029 | 666 |
How it is read
Names in the registry
- “Epcoritamab”, 25 entries
- “Epcoritamab (monotherapy)”, 1 entry
- “Epcoritamab (maintenance)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 7 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Lymphoma, Follicular, 2 studies
- Lymphoma, B-Cell, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.